DocMorris AG (SWX:DOCM)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 239.09M +21.9% |
| Revenue (ttm) | 1.12B +10.6% |
| Net Income | -134.40M |
| EPS | -3.47 |
| Shares Out | 48.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,247 |
| Average Volume | 267,079 |
| Open | 4.96 |
| Previous Close | 4.97 |
| Day's Range | 4.87 - 5.07 |
| 52-Week Range | 3.92 - 24.90 |
| Beta | 1.63 |
| RSI | 55.45 |
| Earnings Date | Mar 19, 2026 |
About DocMorris AG
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma ... [Read more]
Financial Performance
In 2025, DocMorris AG's revenue was 1.12 billion, an increase of 10.56% compared to the previous year's 1.02 billion. Losses were -134.40 million, 38.2% more than in 2024.
Financial StatementsNews
Online drug retailer DocMorris meets expectations as cost savings help
Swiss online drug retailer DocMorris met expectations on Thursday as it released its full-year results for 2023, helped by structural cost savings.
Online drug retailer DocMorris trims top end of 2023 outlook
Swiss online drug retailer DocMorris on Thursday narrowed down the higher end of its annual core loss forecast, citing weaker development in the paper prescription business.